ESMO VIRTUAL ADVANCED COURSE ON
EGFR-MUTATED NSCLC:
A RAPIDLY EVOLVING PARADIGM WITH UNANSWERED QUESTIONS
21-22-23 June 2021

CO-CHAIRS:  Pasi A. Jänne, United States
              Tony S. K. Mok, Hong Kong
              Solange Peters, Switzerland

SPEAKERS:    Fabrice Barlesi, France
              Reinhard Büttner, Germany
              Natasha Leightly, Canada
              Keunchil Park, South Korea
              Antonio Passaro, Italy
              Luis Paz-Ares, Spain
              Frédérique Penault-Llorca, France
              Masahiro Tsuboi, Japan
              James C.-H. Yang, Taiwan

LEARNING OBJECTIVES

• Understanding the biology of EGFR in normal and malignant cells
• Gaining insights in the spectrum of EGFR activating mutations, platforms, and strategies for molecular testing
• Understanding the role of biomarkers in selecting NSCLC patients for EGFR TKIs
• Discussing state-of-the-art therapeutic strategies and clinical research in EGFR mutated NSCLC
• Managing toxicity and how to use EGFR TKIs in specific subgroups of patients

All timings are to be considered GMT+8 (Singapore Local Time)

Monday, 21 June 2021

15:00-15:10  Welcome and introduction
            Pasi A. Jänne, US
            Tony S.K. Mok, HK
            Solange Peters, CH

15:10-16:00  Session 1
            20’  The structure, function and role of EGFR in normal cell homeostasis
                 Reinhard Büttner, DE

            20’  EGFR activating mutations from a molecular biology perspective: Incidence and biology
                 Frédérique Penault-Llorca, FR

            10’  Discussion
16:00-16:10  Break

16:10-17:20  Session 2
20’  Single agent EGFR inhibitor for classical exon 19/21 mutations
Luis Paz-Ares, ES

20’  Treatment of uncommon EGFR mutations (except exon 20)
Antonio Passaro, IT

20’  Treatment of exon 20 mutation
Pasi A. Jänne, US

10’  Discussion

17:20-18:15  Session 3
20’  Resistance to EGFR TKIs: Biological and clinical perspective
Pasi A. Jänne, US

20’  New drugs in development for EGFR TKIs resistance
Tony S. K. Mok, HK

15’  Discussion

18:15-18:45  Session 4
20’  Third generation EGFR TKIs for the first line management of patients EGFR-mutated NSCLC: the clinical evidence and ongoing clinical research
Keunchil Park, KR

10’  Discussion

18:45-19:00  Questions and answers

Tuesday, 22 June 2021

15:00-15:30  Session 5
20’  Immunotherapy for EGFR mutated NSCLC
Solange Peters, CH

10’  Discussion

15:30-16:00  Session 6
20’  Management of CNS metastases/leptomeningeal disease
Natasha Leigl, CA

10’  Discussion
16:00-16:45  Session 7
Debate: Combinations of chemotherapy and EGFR TKIs in EGFR-mutated NSCLC

20'  Added value
James C.-H. Yang, TW

20'  Overtreatment
Natasha Leighl, CA

5'  Voting

16:45-16:55  Break

16:55-17:25  Session 8
20'  The role of EGFR TKIs in the adjuvant and neo-adjuvant setting
Masahiro Tsuboi, JP

10'  Discussion

17:25-17:40  Questions and answers

Wednesday, 23 June 2021

15:00-17:25  Workshop sessions
15' Introduction based on clinical cases presented by speakers
30' Discussion

Workshop 1  Liquid biopsy applications for EGFR mutational profiling and monitoring of disease course
45' Natasha Leighl, CA
Tony S. K. Mok, HK

Workshop 2  Platforms and optimal sequence strategies for NSCLC molecular testing in the molecular oncology era
45' Frédérique Penault-Llorca
Solange Peters, CH

16:30-16:40  Break

Workshop 3  Integrating EGFR TKIs in the management of advanced NSCLC patients with oligometastatic disease and progression in sanctuary sites
45' Fabrice Barlesi, FR
Pasi A. Jänne, US
17:25-17:45  Synthesis and wrap-up
Pasi A. Jänne, US
Tony S.K. Mok, HK
Solange Peters, CH